Key Takeaways
- Strong profit conversion on export rebound: PAT rose 34% YoY as gross margin expanded 421 bps, driven by export normalization and new products, while domestic demand was disrupted by excessive rainfall.
- Domestic volumes grew but prices bit: H1 domestic revenue grew just 5% despite 12% volume growth in Q2, because prices declined ~15% on average. Management expects no further price drops in H2.
- Export engine restarted, not restructured: Export share jumped from ~11% to ~17% of H1 revenue, led by the off-patent portfolio and LATAM recovery. Management explicitly denied any China-to-India sourcing shift.
- Margin guidance is deliberately conservative: Q2 EBITDA margin hit ~24-25% but full-year guidance stays at 18-20%, because rabi season is structurally lower and competition may force price matching.
- What to watch next quarter: Whether rabi demand materializes as strongly as reservoir levels suggest, the pace of Dahej capex finalization, and if the 18-20% margin floor holds when Q3 seasonality kicks in.
Profitability & Margin Dynamics
- Gross margin leap: Expanded 421 bps YoY to 42.6% in Q2, attributed to new product introductions, normalization of export markets that had been burdened by high inventories last year, and rigorous procurement cost optimization.
- Operating leverage delivered: Employee and other operating expenses remained stable, so the gross profit expansion translated directly into EBITDA growth of 31% YoY and PAT growth of 34% YoY.
- Full-year margin anchor at 18-20%: Management repeatedly guided to this range, calling it "realistic" and "a very healthy profitability range." Q2's 24-25% is not the new normal because Q3 and Q4 historically deliver lower sales and EBITDA. In FY23, Q2 was 24.8% but Q3 fell to 16% and Q4 to 12%, yet the full year still landed in the 18-20% band.
- Rabi season structural drag: Rabi margins are always lower than kharif. Management flagged that competition "will behave a little differently in rabi season," potentially forcing price matching that compresses margins.
- Input cost stability assumed: Management believes input costs will not rise significantly and end-market prices will not fall drastically, describing the current situation as "a very healthy, balanced situation." This assumption underpins the margin guidance.
- Inventory efficiency improved: Absolute inventory held flat at INR564 crores despite business growing 10-15%, meaning inventory days have improved. The company deliberately invested more in raw materials and intermediates to insulate against volatile price movements.
Chetan Shah: "I don't think personally that input cost is going to go up significantly. And I don't think that the prices of products in the end-market is going to fall drastically. So it's a very healthy, balanced situation that we are in today."
Domestic Demand: Volume Resilience, Price Pain
- Rain disrupted the spray cycle: Continuous rains in August and September interrupted consumption at ground level, costing farmers an estimated 1-2 sprays of crop protection activities. Q2 domestic revenue declined 3% YoY but volumes grew 12%, revealing the extent of price erosion.
- Price decline of ~15% in H1: Management confirmed a 10-15% average price decline in the first half, already factored into results. No further price drop is expected in H2, but the year-on-year delta will remain negative, though narrower than H1's impact.
- Cotton acreage contracted sharply: Area declined ~10% overall, with northern India seeing a nearly 40% drop. Low commodity prices pushed farmers toward corn and paddy, while pink bollworm infestation compounded the problem. Management expects cotton area to bounce back in other geographies but not in the north.
- Full-year domestic growth trimmed: Earlier aspirations of 10-15% domestic growth have been revised to about 9-10% for the full year, reflecting the Q2 disruption.
- Rabi setup looks favourable: Above-average monsoon rainfall, reservoir levels at 87% of capacity (higher than last year), and ample soil moisture are expected to encourage higher rabi acreage and drive robust agrochemical demand in H2. The government's food grain production target of 3,415.5 crore tons, a 3% increase, adds a policy tailwind.
Chetan Shah: "We say that we are still haunted by rabi season figures always been lower than kharif. So we need to be mindful of that. Because the companies or the competition will behave a little differently in rabi season."
Export Recovery
- Export share surged: Exports jumped from ~11% to ~17% of H1 revenue, driven by normalization of demand after last year's excess inventory destocking. Key geographies: Japan (up 122% YoY) and South America (up 167% YoY).
- Composition tilted toward off-patent: About 75% of exports come from third-party customers in the off-patent segment (the erstwhile Excel Crop Care portfolio), with the remaining 25% from the parent company. Specialty product exports to the parent continue at normal levels.
- LATAM recovery, not restructuring: 80% of LATAM revenue is Brazil, where demand looks good as the season opens. Management explicitly denied any sourcing shift from China to India, stating the growth is purely better demand and volumes as inventory was washed away. Argentina faces foreign exchange issues but is not material for Sumitomo.
- Product-level drivers named: Tebuconazole, Chlorpyriphos, Fluroxypyr, and Clothianidin drove export growth across both fungicides and herbicides. Individual product contributions were not quantified.
- Export margins not structurally higher: When an analyst probed whether new export orders carried higher margins, management redirected to overall business performance, stating the margin expansion was "comprehensive growth in the business" and not attributable to a few high-margin export orders. Per-kg EBITDA in exports has been maintained.
Kunal Mittal: "I think what Shah san commented gives a good comprehensive picture of the total business, both domestic and exports, and it was not like a few particular exports order of higher margin. This was comprehensive growth in the business, and it should be read that way."
New Products & Portfolio Evolution
- New products scaling fast: Products launched in the last 2-3 years grew 65% YoY and now contribute 8-9% of revenue, up from 3-4% last year. Six products were launched in H1: Portion, Ormie, Tribasic Copper (two brands), and Yunico (two formulations).
- Growth target set at 20-25%: Management targets at least 20-25% year-on-year growth on new molecules and brands, calling that "a very decent growth" rate. Absolute product-wise revenue numbers were declined.
- Biologicals pipeline building: Discussions are ongoing with Valent BioSciences; some products have already been launched, some are under development, and others are in the pipeline. The company is also evaluating the portfolio of another green chemistry company acquired globally last year, for potential introduction in India.
- Barrix approaching breakeven: The biologicals subsidiary showed significant growth in the current year versus past trends and was very close to breakeven last year. Current-year growth is adding directly to the bottom line. By year-end, Barrix as a standalone entity would have completed its turnaround, though its contribution will not be material relative to total SCIL numbers for the next 2-3 years.
- Farm equipment and IT chemicals still distant: Discussions with the parent company and global affiliates on farm equipment are in the planning stage, with no short-term contribution expected. IT chemicals and semiconductor-related opportunities remain at the drawing board and discussion stage.
Kunal Mittal: "If we get at least a 20% – 25% growth on these molecules or these brands year-on-year, I think that itself is a very decent growth."
Capex & Capacity Expansion
- Dahej EC clearance secured: Environmental clearance was received without any specific conditions, covering all products as per the application. The company is now on a "speedy path of deciding and getting ready to implement the project."
- Dahej Phase 1 still in planning: The first phase is planned north of INR300 crores, with the overall capex cycle expected to run 2-3 years for Phase 1 alone. Construction should "definitely start beginning in 2026." Product clusters for Phase 1 and Phase 2 are being decided, with one phase dedicated to manufacturing products introduced by the Japanese parent.
- Asset turn guidance: At maturity, revenue potential is expected to be 2x the capex size, with plants taking 2-3 years for full 100% capacity ramp-up. Management declined to confirm an analyst's extrapolation of INR600 crores peak revenue by FY29-30.
- Bhavnagar progressing: One of the two plants has started full-level production and full-level business, targeting full commercialization of products for shipment to the parent company and global affiliates. The two plants have roughly 50-50 revenue potential. Revenue from the INR100-crore capex on five molecules is expected to show growth next year over the current year.
- Tarapur still stalled: The situation remains unchanged from the last call; the plant is not at a robust level of production. Full production targets have been shifted to FY26. Management is "waiting and watching."
Chetan Shah: "I'm happy to inform you that, yes, last month, or during this month, we received the EC clearance without any specific conditions. And it is whatever was our application, we got clearance on all our products."
Strategic Initiatives & Market Positioning
- EDFD campaign scaled up: A 100-day pan-India "Every Day Farmer's Day" campaign ran from June to September 2024, involving ~17,000 meetings, over 5.5 lakh farmers, and 17,000-plus channel partners. Phase 2 is planned from November 2024 to February 2025, coinciding with the rabi season and serving as a pre-launch initiative for "highly anticipated blockbuster product launches."
- Drone application endorsed: The company has applied for drone spraying registrations and already has a couple of products endorsed for drone application. No specific partnership with any drone company exists.
- China competition managed via premium positioning: China has excess capacity and continues to supply depending on the situation. Sumitomo's strategy is to position itself by demonstrating the "premiumness" of its products, which management says has been successful so far.
- Volume growth prioritized: Management focused on volume growth during the first six months through close monitoring and suitable corrections in both purchase and sales pricing, while maintaining stable profitability. H1 volume growth of 15-16% was described as encouraging.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Full-year domestic revenue growth | ~9-10% (revised from 10-15%) | FY25 |
| Full-year EBITDA margin | 18-20% range | FY25 |
| New product/molecule growth | At least 20-25% YoY | Annual, ongoing |
| Dahej Phase 1 construction start | Beginning in 2026 | 2026 |
| Dahej Phase 1 capex cycle | 2-3 years for Phase 1 | From construction start |
| Dahej asset turn at maturity | 2x capex size | 2-3 years post-construction for full ramp-up |
| Tarapur full production | Shifted to FY26 | FY26 |
| Bhavnagar plant 1 full revenue | Current financial year | FY25 |
| Bhavnagar plant 2 growth | Growth next year over current year | FY26 |
| Export growth vs domestic | Export growth percentage higher than domestic (lower base) | FY25 |
Key Metrics
| Metric | Q2 FY25 |
|---|---|
| Revenue | ₹995 cr, up 9% YoY and 18% QoQ |
| Gross margin | 42.6%, up 421 bps YoY and 365 bps QoQ |
| EBITDA | ₹245 cr, up 31% YoY and 52% QoQ |
| EBITDA margin | 24.8%, up 402 bps YoY |
| Profit after tax | ₹193 cr, up 34% YoY and 52% QoQ |
| PAT margin | 19.5%, up 360 bps YoY |
| H1 revenue | ₹1,827 cr, up 12% YoY |
| H1 EBITDA margin | 22.2%, up from 16.5% in H1 FY24 |
| H1 PAT | ₹319 cr, up 56% YoY |
| Domestic volume growth (Q2) | ~12%, offsetting a 15% average price decline |
| H1 volume growth | 15% to 16% |
| Export share of revenue (H1) | 17%, up from 11% in H1 FY24 |
| New product sales growth (H1) | 65% YoY, contributing 8% to 9% of revenue |
| H1 export growth to South America | 167% YoY |
| H1 export growth to Japan | 122% YoY |
| Inventory days | 96 days, flat YoY with inventory at ~₹565 cr |